

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2024

Commission File Number: 001-41440

Virax Biolabs Group Limited  
(Registrant's Name)

BioCity Glasgow  
Bo'Ness Road Newhouse  
Lanarkshire, ML1 5UH  
United Kingdom  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

When used in this Form 6-K, unless otherwise indicated, the terms “the Company,” “Virax,” “we,” “us” and “our” refer to Virax Biolabs Group Limited, and its subsidiaries.

**Information Contained in this Form 6-K Report**

On December 10, 2024, Virax Biolabs Group Limited issued a press release announcing that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland.

A copy of the press release dated December 10, 2024 is included as Exhibit 99.1 to this report.

**Exhibits**

<u>Exhibit No</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press release dated December 10, 2024</a>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VIRAX BIOLABS GROUP LIMITED

Date: December 10, 2024

By: /s/ James Foster  
James Foster, Chief Executive Officer

---



## **Virax Biolabs Announces Agreement with Teubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland**

LONDON, December 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a non-exclusive distribution agreement with French company to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland.

"We are honored to announce this agreement with Teubio, who will prove to be instrumental in increasing the accessibility of ImmuneSelect for life science institutions across a crucial market such as Europe," said **James Foster, CEO of Virax Biolabs**. "This agreement further strengthens our ongoing efforts to advance immune profiling technology and supports a growing need for comprehensive insights into immune health status through ImmuneSelect."

"This collaboration with Virax holds a great significance for our company as it demonstrates our commitment to innovative diagnostic tools such as ImmuneSelect," said **Romain Cordonnier-Goulay, CSO of Teubio**. "Our strong distribution networks and relations across Europe will help ImmuneSelect become more accessible to customers to help with their research needs."

### **About ImmuneSelect**

ImmuneSelect is the Company's portfolio of research products dedicated to investigating adaptive immunity. Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens, optimized for the stimulation of T cells. The initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 ("CD8"), Lyme Disease, Cytomegalovirus ("CMV"), Respiratory Syncytial Virus ("RSV") and Epstein-Barr Virus ("EBV"), which continue to be regularly expanded. ImmuneSelect's Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to be tested on a range of applications including Flow Cytometry, ELISA and ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is compatible with most standard laboratory equipment.

### **About Virax Biolabs Group Limited**

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.

For more information, please visit [www.viraxbiolabs.com](http://www.viraxbiolabs.com).

### **About Teubio**

We facilitate Life Sciences Research every day, contributing to advance Science for a brighter future. Through our Teubio local offices located across Europe, we support Life Sciences and Biotechnology Researchers with a unique, holistic range of solutions to advance their projects faster. With Teubio, concentrate your efforts and accelerate what's most important to you: Your Research.

For more information, please visit

### **Investor Relations Contact:**

Russo Partners, LLC

Nic Johnson

12 West 27th Street

4th Floor

New York, NY 10001

M: 303-482-6405

[nic.johnson@russopartnersllc.com](mailto:nic.johnson@russopartnersllc.com)

---

